Overview

A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety of eszopiclone (2, 3 mg) in non-elderly patients with insomnia and eszopiclone (1, 2 mg) in elderly patients with insomnia.
Phase:
Phase 3
Details
Lead Sponsor:
Eisai Co., Ltd.
Treatments:
Eszopiclone